RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m6A-GLUT1-mTORC1 Axis and Is a Therapeutic Target

2020/11/18 by Huarong Chen, Shanshan Gao, Weixin Liu +14 · 25 citations
Biochemistry, Genetics and Molecular Biology · #RNA modifications and cancer #Cancer-related gene regulation #Cancer-related molecular mechanisms research

paper · pdf · doi:10.1053/j.gastro.2020.11.013

Cited by

• CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement. [europepmc]
• The evolving landscape of N 6 -methyladenosine modification in the tumor microenvironment. [europepmc]
• The Emerging Clinical Application of m6A RNA Modification in Inflammatory Bowel Disease and Its Associated Colorectal Cancer. [europepmc]
• N6-methyladenosine methyltransferases: functions, regulation, and clinical potential. [europepmc]
• Fusobacterium nucleatum reduces METTL3-mediated m 6 A modification and contributes to colorectal cancer metastasis. [europepmc]
• Roles of RNA Modifications in Diverse Cellular Functions. [europepmc]
• SLC2A1 is a Diagnostic Biomarker Involved in Immune Infiltration of Colorectal Cancer and Associated With m6A Modification and ceRNA. [europepmc]
• Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas. [europepmc]
• Role of main RNA modifications in cancer: N 6 -methyladenosine, 5-methylcytosine, and pseudouridine. [europepmc]
• Crosstalk among m 6 A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application. [europepmc]
• Alternative splicing of METTL3 explains apparently METTL3-independent m6A modifications in mRNA. [europepmc]
• Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1/GLUT1 enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma. [europepmc]
• METTLing in Stem Cell and Cancer Biology. [europepmc]
• Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer. [europepmc]
• IGF2BP3 is an essential N 6 -methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells. [europepmc]
• METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey. [europepmc]
• Metabolic reprogramming in colorectal cancer: regulatory networks and therapy. [europepmc]
• The roles and implications of RNA m 6 A modification in cancer. [europepmc]
• Methyltransferase-like proteins in cancer biology and potential therapeutic targeting. [europepmc]
• Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer. [europepmc]
• METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy. [europepmc]
• Intracellular Fusobacterium nucleatum infection increases METTL3-mediated m6A methylation to promote the metastasis of esophageal squamous cell carcinoma. [europepmc]
• RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy. [europepmc]
• The role of RNA methylation in tumor immunity and its potential in immunotherapy. [europepmc]
• Glycolysis in the tumor microenvironment: a driver of cancer progression and a promising therapeutic target. [europepmc]